Follow The Filings

JBIO Jade Biosciences Inc.

Health Care, filed as JADE BIOSCIENCES INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 6.1%
  • $41M
  • 1 add 1 reduce

In 2026 Q2 David Witzke added to Jade Biosciences, while James Silverman trimmed.

Who owns this now

Largest portfolio weights among holders, up to 6.1% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke Add 6.1%
  2. James Silverman Reduce 0.29%

Who owns JBIO

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 6.1% Add +21.4% 1,700,708 $38M History
James Silverman, Opaleye Management 0.29%, was 0.79% Reduce −66.1% 145,000 $3.2M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by JBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All JBIO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
DEFA14A Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
424B3 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B3 Filing Doc
424B3 Filing Doc
DEF 14A Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$75.52M -$69.63M -$127.41M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $124.23M $80.12M $348.82M
Total non-current assets * $3.19M $0.215M $0.965M
Total assets $127.42M $80.33M $349.78M
Total current liabilities $17.64M $3.83M $16.54M
Total non-current liabilities * $325,000 $70,000 $724,000
Total equity $109.46M $76.43M $332.52M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$56.78M -$71.2M -$94.69M
Cash from investing $11.88M $56.03M -$247.01M
Cash from financing $46M $25.43M $360.77M
Net change in cash $1.09M $10.26M $19.05M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.